Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases

Table 5

Subgroup analyses of patients with different connective tissue diseases.

Subgroups	Parameters (, %)	Groups			values			Overall
		Group A: Ro52 alone	Group B: Ro60 alone	Group C: Ro60 and Ro52	Group A vs. group B	Group A vs. group C	Group B vs. group C
SLE	All	31 (18.3)	136 (48.1)	450 (51.9)	<0.0001	<0.0001	0.261	<0.0001
	Skin rash	6 (19.4)	66 (48.5)	134 (29.8)	0.003	0.217	<0.0001	<0.0001
	Arthralgia	10 (32.3)	82 (60.3)	137 (30.4)	0.005	0.832	<0.0001	<0.0001
	Myalgia	1 (3.2)	16 (11.8)	12 (2.7)	0.276	1.000	<0.0001	<0.0001
	IgG>18 g/L	15 (53.6)	28 (22.2)	149 (35.5)	0.001	0.054	0.005	0.002
	ANA	19 (61.3)	107 (78.7)	272 (60.4)	0.042	0.926	<0.0001	<0.0001
	ACA-IgG	5 (16.1)	10 (7.4)	21 (4.7)	0.232	0.020	0.220	0.022
	ACA-IgM	4 (12.9)	12 (8.8)	17 (3.8)	0.720	0.051	0.017	0.011
	Anti-βGP1	5 (16.1)	4 (2.9)	14 (3.1)	0.013	0.002	1.000	0.001
	Anti-ds-DNA	17 (54.8)	67 (49.3)	285 (63.3)	0.575	0.344	0.003	0.011
	Anti-La	1 (3.2)	21 (15.4)	142 (31.6)	0.128	0.001	<0.0001	<0.0001
	Infection	11 (35.5)	42 (30.9)	101 (22.4)	0.619	0.097	0.045	0.052
SS	All	27 (16.0)	37 (13.1)	190 (21.9)	0.392	0.083	0.001	0.002
	Xerophthalmia	12 (44.4)	9 (24.3)	114 (60.0)	0.090	0.125	<0.0001	<0.0001
	Xerostomia	12 (44.4)	13 (35.1)	123 (64.7)	0.451	0.042	0.001	0.001
	Arthralgia	11 (40.7)	25 (67.6)	51(26.8)	0.033	0.135	<0.0001	<0.0001
	RP	3 (11.1)	2 (5.4)	4 (2.1)	0.713	0.013	0.559	0.049
	ILD	10 (37.0)	1 (2.7)	30 (15.8)	0.001	0.008	0.034	0.001
	IgG>18 g/L	0 (0)	6 (16.2)	75 (39.5)	0.096	<0.0001	<0.0001	<0.0001
	ANA	12 (44.4)	23 (62.2)	150 (78.9)	0.160	<0.0001	0.028	<0.0001
	Anti-La	3 (11.1)	3 (8.1)	91( 47.9)	1.000	<0.0001	<0.0001	<0.0001
ILD	All	60 (35.5)	32 (11.3)	119 (13.7)	<0.0001	<0.0001	0.296	<0.0001
	SLE	4 (6.7)	10 (31.2)	37 (31.1)	0.004	<0.0001	0.986	0.001
	UCTD	15 (25.0)	12 (37.5)	19(16.0)	0.193	0.162	0.007	0.026
	pSS	10 (16.7)	1 (3.1)	30 (25.2)	0.122	0.178	0.006	0.015
	IM	20 (33.3)	0 (0)	10 (8.4)	<0.0001	<0.0001	0.195	<0.0001

SLE: systemic lupus erythematosus; pSS: primary Sjögren’s syndrome; SSc: systemic sclerosis; ANA: anti-nuclear antibodies; ACA-IgG: Anti-cardiolipin antibodies IgG; ACA-IgM: Anti-cardiolipin antibodies IgM; Anti-βGP1: Anti-β2-glycoprotein antibodies; Anti-ds-DNA: anti-double-stranded DNA antibodies; RP: Raynaud’s phenomenon; ILD: interstitial lung disease. A total of 42 patients with SLE did not have serum IgG tested.